| 000 | 01888 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518080235.0 | ||
| 264 | 0 | _c20210112 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1742-6405 | ||
| 024 | 7 |
_a10.1186/s12981-019-0257-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChan, Phillip | |
| 245 | 0 | 0 |
_aNeuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. _h[electronic resource] |
| 260 |
_bAIDS research and therapy _c01 2020 |
||
| 300 |
_a1 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aData Analysis |
| 650 | 0 | 4 |
_aDrug Substitution _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Integrase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 3-Ring _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMental Disorders _xetiology |
| 650 | 0 | 4 |
_aMood Disorders _xetiology |
| 650 | 0 | 4 |
_aOxazines _xadverse effects |
| 650 | 0 | 4 |
_aPiperazines _xadverse effects |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aPyridones _xadverse effects |
| 700 | 1 | _aGoh, Orlanda | |
| 700 | 1 | _aKroon, Eugène | |
| 700 | 1 | _aColby, Donn | |
| 700 | 1 | _aSacdalan, Carlo | |
| 700 | 1 | _aPinyakorn, Suteeraporn | |
| 700 | 1 | _aPrueksakaew, Peeriya | |
| 700 | 1 | _aReiss, Peter | |
| 700 | 1 | _aAnanworanich, Jintanat | |
| 700 | 1 | _aValcour, Victor | |
| 700 | 1 | _aSpudich, Serena | |
| 700 | 1 | _aPaul, Robert | |
| 773 | 0 |
_tAIDS research and therapy _gvol. 17 _gno. 1 _gp. 1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12981-019-0257-8 _zAvailable from publisher's website |
| 999 |
_c30488955 _d30488955 |
||